<p>Candel Therapeutics, Inc. (NASDAQ:CADL - 獲取免費報告) 在覆蓋該股票的八家評級公司中被賦予了 “適度買入” 的平均推薦，MarketBeat 報道。一位研究分析師對該股票給予了賣出評級，一位給予了持有評級，五位給予了買入評級，還有一位給予了強烈買入評級。在過去一年中，發佈報告的分析師對該股票的平均 12 個月目標價為$18.3333。</p>
<p>獲取 <strong>Candel Therapeutics</strong> 警報：</p>
<ul>
<li>異常高的交易量指向這些股票的上漲潛力</li>
</ul>
<p>CADL 最近成為幾份研究報告的主題。HC Wainwright 在 9 月 29 日的研究報告中重申了對 Candel Therapeutics 的 “買入” 評級，並設定了$23.00 的目標價。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Candel Therapeutics 的 “賣出 (d-)” 評級。花旗集團在 11 月 14 日的報告中將 Candel Therapeutics 的目標價從$25.00 下調至$24.00，並對該公司設定了 “買入” 評級。Lifesci Capital 在 10 月 21 日的報告中開始覆蓋 Candel Therapeutics。他們對該股票設定了 “跑贏大盤” 評級和$16.00 的價格目標。最後，華爾街禪在 11 月 15 日的研究報告中將 Candel Therapeutics 的評級從 “持有” 下調至 “賣出”。</p>
<p><strong>查看我們關於 CADL 的最新研究報告</strong></p>
<h2>Candel Therapeutics 的機構交易</h2>
<p>對該公司的對沖基金最近增加或減少了其持股。Acorn Capital Advisors LLC 在第二季度將其在 Candel Therapeutics 的持股增加了 19.9%。Acorn Capital Advisors LLC 現在擁有 2580517 股該公司的股票，價值 13057000 美元，在上個季度額外購買了 428265 股。先鋒集團在第三季度將其在 Candel Therapeutics 的持股增加了 12.3%。先鋒集團現在擁有 2007112 股該公司的股票，價值 10236000 美元，在上個季度額外購買了 219563 股。Geode Capital Management LLC 在第二季度將其在 Candel Therapeutics 的持股增加了 31.5%。Geode Capital Management LLC 現在擁有 903970 股該公司的股票，價值 4575000 美元，在上個季度額外購買了 216509 股。Halter Ferguson Financial Inc. 在第二季度將其在 Candel Therapeutics 的持股增加了 12.0%。Halter Ferguson Financial Inc. 現在擁有 776516 股該公司的股票，價值 3929000 美元，在上個季度額外購買了 83363 股。最後，Tanager Wealth Management LLP 在第二季度獲得了 Candel Therapeutics 的新頭寸，價值 995000 美元。機構投資者和對沖基金持有該公司 13.93% 的股票。</p>
<h2>Candel Therapeutics 股票表現</h2>
<p>Candel Therapeutics 股票在週五開盤價為$5.65。該股票的市值為 3.1019 億美元，市盈率為-9.91，貝塔值為-0.94。該公司的債務與股本比率為 0.01，流動比率為 8.25，速動比率為 8.25。該業務的 50 日移動平均線為$5.27，200 日移動平均線為$5.52。Candel Therapeutics 的 12 個月低點為$4.25，12 個月高點為$13.68。</p>
<p>Candel Therapeutics (NASDAQ:CADL - 獲取免費報告) 最近在 11 月 13 日發佈了季度財報。該公司報告每股收益（EPS）為 ($0.21)，低於分析師共識預期的 ($0.17) $0.04。作為一個整體，賣方分析師預測 Candel Therapeutics 在本年度將發佈-1.47 的每股收益。</p>
<h2>關於 Candel Therapeutics</h2>
<p>(獲取免費報告)</p>
<p>Candel Therapeutics NASDAQ: CADL 是一家臨牀階段的免疫腫瘤學公司，專注於開發下一代溶瘤病毒療法，旨在治療實體腫瘤。該公司的主要候選藥物 CAN-2409 是一種局部給藥的基因遞送病毒療法，旨在選擇性地在癌細胞中複製並誘導免疫原性細胞死亡。Candel 利用專有的病毒工程平台來增強腫瘤特異性複製並刺激抗腫瘤免疫反應，旨在改善高未滿足醫療需求患者的治療效果。</p>
<p>除了其主要項目外，Candel 的管線還包括 CAN-3110，一種針對複發性高等級膠質瘤的溶瘤單純皰疹病毒，以及其他正在探索的針對各種實體腫瘤適應症的新型病毒構建體。</p>
<h2>另見</h2>
<ul>
<li>五隻我們認為比 Candel Therapeutics 更好的股票</li>
<li>黃金警報</li>
<li>如果你在美國銀行賬户中存現金……請立即閲讀此內容</li>
<li>沒有人告訴你的 100 萬億美元的人工智能故事</li>
<li>關於中國的震撼揭露</li>
<li>請勿刪除，立即閲讀</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FETA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FETA"/></p>
<p><em>此即時新聞警報由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Candel Therapeutics 嗎？</h2>
<p>在你考慮 Candel Therapeutics 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Candel Therapeutics 並不在名單上。</p>
<p>雖然 Candel Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

CADL

<p>Candel Therapeutics, Inc.（納斯達克代碼：CADL）獲得了八家券商的 “適度買入” 共識評級。該股票有一個賣出評級、一個持有評級、五個買入評級和一個強烈買入評級。12 個月的平均目標價格為 18.33 美元。最近的報告包括 HC Wainwright 重申的買入評級，目標價為 23 美元，以及花旗集團下調的目標價。Candel 的股票開盤價為 5.65 美元，市值為 3.1019 億美元。該公司報告的季度每股收益為（0.21 美元），未達到預期。Candel 專注於開發針對實體腫瘤的溶瘤病毒療法</p>

<p>Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) has been assigned an average recommendation of &#34;Moderate Buy&#34; from the eight ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $18.3333.</p>
<div class="lb-trans"><p>Candel Therapeutics, Inc. (NASDAQ:CADL - 獲取免費報告) 在覆蓋該股票的八家評級公司中被賦予了 “適度買入” 的平均推薦，MarketBeat 報道。一位研究分析師對該股票給予了賣出評級，一位給予了持有評級，五位給予了買入評級，還有一位給予了強烈買入評級。在過去一年中，發佈報告的分析師對該股票的平均 12 個月目標價為$18.3333。</p>
</div><p>Get <strong>Candel Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Candel Therapeutics</strong> 警報：</p>
</div><ul>
<li>Unusually High Volume Points to Upside in These Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>異常高的交易量指向這些股票的上漲潛力</li>
</ul>
</div><p>CADL has been the topic of several recent research reports. HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $23.00 target price on shares of Candel Therapeutics in a research note on Monday, September 29th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Candel Therapeutics in a research note on Wednesday, October 8th. Citigroup decreased their target price on Candel Therapeutics from $25.00 to $24.00 and set a &#34;buy&#34; rating for the company in a report on Friday, November 14th. Lifesci Capital initiated coverage on Candel Therapeutics in a report on Tuesday, October 21st. They set an &#34;outperform&#34; rating and a $16.00 price target on the stock. Finally, Wall Street Zen lowered Candel Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, November 15th.</p>
<div class="lb-trans"><p>CADL 最近成為幾份研究報告的主題。HC Wainwright 在 9 月 29 日的研究報告中重申了對 Candel Therapeutics 的 “買入” 評級，並設定了$23.00 的目標價。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Candel Therapeutics 的 “賣出 (d-)” 評級。花旗集團在 11 月 14 日的報告中將 Candel Therapeutics 的目標價從$25.00 下調至$24.00，並對該公司設定了 “買入” 評級。Lifesci Capital 在 10 月 21 日的報告中開始覆蓋 Candel Therapeutics。他們對該股票設定了 “跑贏大盤” 評級和$16.00 的價格目標。最後，華爾街禪在 11 月 15 日的研究報告中將 Candel Therapeutics 的評級從 “持有” 下調至 “賣出”。</p>
</div><p><strong>Check Out Our Latest Research Report on CADL</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 CADL 的最新研究報告</strong></p>
</div><h2>Institutional Trading of Candel Therapeutics</h2>
<div class="lb-trans"><h2>Candel Therapeutics 的機構交易</h2>
</div><p>Hedge funds have recently added to or reduced their stakes in the company. Acorn Capital Advisors LLC lifted its stake in Candel Therapeutics by 19.9% in the second quarter. Acorn Capital Advisors LLC now owns 2,580,517 shares of the company's stock worth $13,057,000 after acquiring an additional 428,265 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Candel Therapeutics by 12.3% in the 3rd quarter. Vanguard Group Inc. now owns 2,007,112 shares of the company's stock valued at $10,236,000 after purchasing an additional 219,563 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Candel Therapeutics by 31.5% during the 2nd quarter. Geode Capital Management LLC now owns 903,970 shares of the company's stock worth $4,575,000 after purchasing an additional 216,509 shares during the last quarter. Halter Ferguson Financial Inc. grew its stake in shares of Candel Therapeutics by 12.0% during the second quarter. Halter Ferguson Financial Inc. now owns 776,516 shares of the company's stock worth $3,929,000 after purchasing an additional 83,363 shares in the last quarter. Finally, Tanager Wealth Management LLP acquired a new position in shares of Candel Therapeutics during the second quarter worth $995,000. Institutional investors and hedge funds own 13.93% of the company's stock.</p>
<div class="lb-trans"><p>對該公司的對沖基金最近增加或減少了其持股。Acorn Capital Advisors LLC 在第二季度將其在 Candel Therapeutics 的持股增加了 19.9%。Acorn Capital Advisors LLC 現在擁有 2580517 股該公司的股票，價值 13057000 美元，在上個季度額外購買了 428265 股。先鋒集團在第三季度將其在 Candel Therapeutics 的持股增加了 12.3%。先鋒集團現在擁有 2007112 股該公司的股票，價值 10236000 美元，在上個季度額外購買了 219563 股。Geode Capital Management LLC 在第二季度將其在 Candel Therapeutics 的持股增加了 31.5%。Geode Capital Management LLC 現在擁有 903970 股該公司的股票，價值 4575000 美元，在上個季度額外購買了 216509 股。Halter Ferguson Financial Inc. 在第二季度將其在 Candel Therapeutics 的持股增加了 12.0%。Halter Ferguson Financial Inc. 現在擁有 776516 股該公司的股票，價值 3929000 美元，在上個季度額外購買了 83363 股。最後，Tanager Wealth Management LLP 在第二季度獲得了 Candel Therapeutics 的新頭寸，價值 995000 美元。機構投資者和對沖基金持有該公司 13.93% 的股票。</p>
</div><h2>Candel Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Candel Therapeutics 股票表現</h2>
</div><p>Shares of Candel Therapeutics stock opened at $5.65 on Friday. The stock has a market capitalization of $310.19 million, a price-to-earnings ratio of -9.91 and a beta of -0.94. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.25 and a quick ratio of 8.25. The business has a 50-day moving average of $5.27 and a 200 day moving average of $5.52. Candel Therapeutics has a 12 month low of $4.25 and a 12 month high of $13.68.</p>
<div class="lb-trans"><p>Candel Therapeutics 股票在週五開盤價為$5.65。該股票的市值為 3.1019 億美元，市盈率為-9.91，貝塔值為-0.94。該公司的債務與股本比率為 0.01，流動比率為 8.25，速動比率為 8.25。該業務的 50 日移動平均線為$5.27，200 日移動平均線為$5.52。Candel Therapeutics 的 12 個月低點為$4.25，12 個月高點為$13.68。</p>
</div><p>Candel Therapeutics (NASDAQ:CADL - Get Free Report) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.04). As a group, sell-side analysts forecast that Candel Therapeutics will post -1.47 earnings per share for the current year.</p>
<div class="lb-trans"><p>Candel Therapeutics (NASDAQ:CADL - 獲取免費報告) 最近在 11 月 13 日發佈了季度財報。該公司報告每股收益（EPS）為 ($0.21)，低於分析師共識預期的 ($0.17) $0.04。作為一個整體，賣方分析師預測 Candel Therapeutics 在本年度將發佈-1.47 的每股收益。</p>
</div><h2>About Candel Therapeutics</h2>
<div class="lb-trans"><h2>關於 Candel Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Candel Therapeutics NASDAQ: CADL is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company's lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.</p>
<div class="lb-trans"><p>Candel Therapeutics NASDAQ: CADL 是一家臨牀階段的免疫腫瘤學公司，專注於開發下一代溶瘤病毒療法，旨在治療實體腫瘤。該公司的主要候選藥物 CAN-2409 是一種局部給藥的基因遞送病毒療法，旨在選擇性地在癌細胞中複製並誘導免疫原性細胞死亡。Candel 利用專有的病毒工程平台來增強腫瘤特異性複製並刺激抗腫瘤免疫反應，旨在改善高未滿足醫療需求患者的治療效果。</p>
</div><p>In addition to its lead program, Candel's pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.</p>
<div class="lb-trans"><p>除了其主要項目外，Candel 的管線還包括 CAN-3110，一種針對複發性高等級膠質瘤的溶瘤單純皰疹病毒，以及其他正在探索的針對各種實體腫瘤適應症的新型病毒構建體。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Candel Therapeutics</li>
<li>GOLD ALERT</li>
<li>If You Keep Cash In A U.S. Bank Account… Read This NOW</li>
<li>The $100 Trillion AI Story No One Is Telling You</li>
<li>Bombshell Exposé on China Strikes</li>
<li>Do not delete, read immediately</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Candel Therapeutics 更好的股票</li>
<li>黃金警報</li>
<li>如果你在美國銀行賬户中存現金……請立即閲讀此內容</li>
<li>沒有人告訴你的 100 萬億美元的人工智能故事</li>
<li>關於中國的震撼揭露</li>
<li>請勿刪除，立即閲讀</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FETA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CADL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Candel Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Candel Therapeutics 嗎？</h2>
</div><p>Before you consider Candel Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Candel Therapeutics 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Candel Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Candel Therapeutics 並不在名單上。</p>
</div><p>While Candel Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Candel Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Candel Therapeutics, Inc. (NASDAQ:CADL) 被券商一致評為 “適度買入”